Meeting
2020 Genitourinary Cancers Symposium
Novel risk scoring system for metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (C).
Authors
Meredith R Kline
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA
Meredith R Kline , Dylan J. Martini , Yuan Liu , Julie M. Shabto , Bradley Curtis Carthon , Elise Hitron , Greta Russler , Sarah Caulfield , Lauren Beth Yantorni , Wayne Harris , Omer Kucuk , Viraj A. Master , Mehmet Asim Bilen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 734)
Abstract #
734
Poster Bd #
J10
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
First Author: Dylan J Martini
Poster
2018 ASCO Annual Meeting
Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.
First Author: Dominick Bossé
Poster
2023 ASCO Genitourinary Cancers Symposium
Cabozantinib + nivolumab in adult patients with advanced or metastatic renal cell carcinoma: A retrospective, non-interventional study in a real-world cohort.
First Author: Thomas Hilser
Poster
2021 ASCO Annual Meeting
Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
First Author: Elizabeth R Kessler